AMicale des COXiens

Forum des actionnaires particuliers de NicOx
 
AccueilAccueil  GalerieGalerie  S'enregistrerS'enregistrer  ConnexionConnexion  

Partagez | 
 

 nicox et william b white déposent toujours des brevets pour le napro

Voir le sujet précédent Voir le sujet suivant Aller en bas 
AuteurMessage
vinsse



Nombre de messages : 515
Date d'inscription : 15/05/2008

MessageSujet: nicox et william b white déposent toujours des brevets pour le napro   Mar 28 Sep - 12:32

http://www.freepatentsonline.com/y2010/0240745.html

METHOD OF TREATMENT OF INFLAMMATION IN HYPERTENSIVE PATIENTS
petit décalage de date avec le "filling" et la publi ...entre temps la fda est passée


09/23/10 - Class 514 site info News monitor Monitor Keywords monitor archive Archive organizer Organizer account info Account | Prev - Next

SEARCH FreshPatents: Monitor Keywords | rss Custom RSS
Method of treatment of inflammation in hypertensive patients
Abstract: The present invention relates to the use of 4-(nitrooxy)-butyl-(S)-2-(6-methoxy-2-naphthyl)-propanoate (naproxcinod) for the treatment of pain and/or inflammation in patients with hypertension treated with renin-angiotensin system blocking agents. (end of abstract - images & description further down the page)

The present invention relates to the use of 4-(nitrooxy)butyl(2S)-2-(6-methoxy-2-naphthyl)propanoate (naproxcinod) for the treatment of inflammation, in particular the treatment of signs or symptoms of musculo-skeletal disorders such as osteoarthritis, in hypertensive patients.

4-(nitrooxy)butyl(2S)-2-(6-methoxy-2-naphthyl)propanoate is a nitric oxide derivative releasing naproxen with reduced gastrointestinal and cardiovascular toxicity, and with analgesic, anti-inflammatory and antipyretic effects (Schnitzer T J. et al; Arthritis Rheum. 2005; 53:827-837).

WO 95/09831 discloses the synthesis of 4-(nitrooxy) butyl (2S)-2-(6-methoxy-2-naphthyl)propanoate and its anti-inflammatory, analgesic, anti-aggregating activities and its reduced gastrointestinal toxicity. WO 95/09831 does not mention the effect of 4-(nitrooxy)butyl(2S)-2-(6-methoxy-2-naphthyl) on blood pressure.

Osteoarthritis and hypertension are commonly observed co-morbidities in elderly patients and co-administration of non-steroidal anti-inflammatory drugs (NSAIDs) with antihypertensive agents is very common in clinical practice (Singh G. et al; Am J Manag Care. 2002; 8(15 suppl): S383-S391, Caporali R. et al. Semin Arthritis Rheum. 2005; 35 (Suppl 1):31-37, White W B. et al; Hypertension. 2004; 44:123-124).
(continued below image...)





Title: Method of treatment of inflammation in hypertensive patients
Agent: Arent Fox LLP
Washington, DC, US
Inventors: Rosa Rosanna B. FLEMING, Brigitte Duquesroix, William B. White
USPTO Applicaton #: #20100240745
USPTO Class: 514509
USPTO Publishing Date: 09/23/10

pdficondownload pdf

METHOD OF TREATMENT OF INFLAMMATION IN HYPERTENSIVE PATIENTS description/claims

NSAIDs are widely used to alleviate pain and inflammation but while they are considered relatively safe for acute and short-term use, there are well known adverse effects in chronic users. In particular, NSAIDs (eg, ibuprofen, indomethacin, and naproxen) could increase mean arterial pressure by as much as 5 to 6 mmHg in hypertensive patients. Pope J E. et al; Arch Intern Med. 1993; 153:477-484, Johnson A G. et al; Ann Intern Med. 1994; 121:289-300.

Moreover, it is well recognised that NSAIDs may also interfere with hypertension management in patients with osteoarthritis and pre-existing hypertension, especially those treated with agents that block the renin-angiotensin system, starting as early as 1 to 3 weeks of initiating NSAID therapy. In such cases, blood pressure destabilization, which may lead to hypertensive complications, commonly develops. Whelton A. et al, Am J Cardiol. 2002, 90:959-963; Morgan T O. et al, Am J Hypertens. 2000, 13:1161-1167; Solomon D H. et al; Hypertension. 2004; 44:140-145.

Based on the foregoing discussion, there is a recognised need for anti-inflammatory drugs to be used in the subpopulation of osteoarthritic patients with treated hypertension.

Surprisingly and unexpectedly, it was found that 4-(nitrooxy)butyl(2S)-2-(6-methoxy-2-naphthyl)propanoate does not induce blood pressure elevation in osteoarthritic hypertensive patients treated with at least a renin-angiotensin system blocking agent.

The present invention is therefore related to a method for the treatment of inflammation, in particular for the treatment of signs or symptoms of musculo-skeletal disorders such as osteoarthritis, comprising administering to a patient with hypertension, who is administered with at least one renin-angiotensin system blocking agent, a therapeutically effective amount of 4-(nitrooxy)butyl(25)-2-(6-methoxy-2-naphthyl)propanoate.

The present invention is further related to a method for the treatment of inflammation, in particular for the treatment of signs or symptoms of musculo-skeletal disorders such as osteoarthritis, comprising administering to a patient with hypertension, who is co-administered with at least a renin-angiotensin system blocking agent and with a diuretic, a therapeutically effective amount of 4-(nitrooxy)butyl(2S)-2-(6-methoxy-2-naphthyl)propanoate. The group of renin-angiotensin system blocking agents (RAS blocking agents) includes ACE inhibitors, angiotensin receptor blockers (ARBs), selective and non selective beta blockers, and renin-inhibitors.

Renin-angiotensin system blocking agents can be taken alone or in combination with a diuretic.

Particularly suitable diuretics are selected from the group of sulfonamide derivatives preferably furosemide, or from the group of thiazide diuretics, for example chlorothiazide, chlorthalidone, hydrochlorothiazide, indapamide, metolazone, polythiazide.

The doses of 4-(nitrooxy)butyl(2S)-2-(6-methoxy-2-naphthyl)propanoate to be administered are determined depending upon, for example, age, body weight, symptoms, the desired therapeutic effects, the route of administration, and the treatment duration. In human adults, single doses administered range generally from 1 mg to 1000 mg, by oral administration, up to several times per day, and from 1 mg to 100 mg, by parenteral administration up to several times per day, or continuous administration for from 1 to 24 hours.

As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases wherein doses lower than or greater than the ranges specified above may be used.

The compound of the present invention may be administered in the form of, for example, solid compositions, liquid compositions or other compositions for oral administration, injections, liniments or suppositories for parenteral administration.

The present invention also provides pharmaceutical kits comprising 4-(nitrooxy)butyl(2S)-2-(6-methoxy-2-naphthyl)propanoate, a renin-angiotensin system blocking agent and optionally a diuretic, as combined preparation for simultaneous, separated or sequential use.

The synthesis of 4-(nitrooxy)butyl(2S)-2-(6-methoxy-2-naphthyl)propanoate is described in the WO 95/09831. The compound has the following formula:

EXPERIMENTAL PART

Effects of 4-(nitrooxy)butyl(2S)-2-(6-methoxy-2-naphthyl)propanoate (naproxcinod) and naproxen on systolic blood pressure (SBP).

The effects of two twice daily drug regimens (375 mg bid and 750 mg bid) of 4-(nitrooxy)butyl(2S)-2-(6-methoxy-2-naphthyl)propanoate (naproxcinod) on systolic blood pressure (SBP) vs. naproxen and placebo were studied in a 13-week double-blind, randomized clinical trial involving 207 osteoarthritic patients and hypertension treated with renin-angiotensin system blockers alone or in combination with a diuretic.

Patients were sequentially randomized in a 1:1:1:1 ratio using a validated remote automated system to receive for the 13-week study treatment period one of 4 treatment groups: naproxcinod 750 mg twice daily, naproxcinod 375 mg twice daily, naproxen 500 mg (equimolar dose of naproxcinod 750 mg) twice daily, or placebo twice daily.

The office SBP was measured in a standardized fashion by mercury column or aneroid device in supine position, at rest, at baseline and 2, 6, and 13 weeks after study treatment initiation. SBP measurements were to be performed 2 to 4 hours post-morning dose.

The comparability of the patients in the 4 treatment groups was determined from the demographic data and baseline BP values.

The data in Table I show that the difference in the mean change from baseline in systolic BP in the naproxcinod 750 mg bid group vs. naproxen 500 mg bid group was −6.5 mmHg.

These results demonstrate that naproxcinod induces less BP destabilization compared to naproxen and that it behaves similarly to placebo in patients with osteoarthritis and treated hypertension.

TABLE I mean changes in systolic blood pressure (SBP) Difference in mean changes of SBP (mmHg) mean ± SE Baseline vs (mmHg) vs vs naproxen Groups mean ± SD baseline placebo 500 mg placebo 127.8 ± (12.Cool −4.6 ± 1.9  — 6.1 naproxen 127.8 ± (12.3)  1.5 ± 1.9**  6.1** — 500 mg naproxcinod 129.2 ± (15.0) −2.7 ± 1.7  1.9 −4.2 375 mg naproxcinod 129.0 ± (12.2) −5.0 ± 1.7* −0.4* −6.5* 750 mg *p < 0.02 vs naproxen 500 mg; ** p < 0.05 vs placebo




et étudie toujours le 4016
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0012874


Revenir en haut Aller en bas
Voir le profil de l'utilisateur
 
nicox et william b white déposent toujours des brevets pour le napro
Voir le sujet précédent Voir le sujet suivant Revenir en haut 
Page 1 sur 1
 Sujets similaires
-
» CRPCEN
» planning toujours la veille
» Un merci ça fait toujours plaisir
» Les femmes ont toujours le dernier mot
» perlerare : mon copain n'est toujours pas juger

Permission de ce forum:Vous ne pouvez pas répondre aux sujets dans ce forum
AMicale des COXiens :: Forum public :: Echanges sur NicOx-
Sauter vers: